MedTrace Logo

Third-line Treatment of Gefitinib in NSCLC Patients

NCT01933347 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2020-02-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the disease control rate (DCR) of gefitinib as third-line retreatment in stage IIIB/IV NSCLC with EGFR 19del/L858R positive mutation patients who had benefited from first-line gefitinib treatment with EGFR 19del/L858R positive mutation and tumor progression after the second-line chemotherapy

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Gefitinib

Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression.

Sponsors & Collaborators

  • Guangdong Association of Clinical Trials

    lead OTHER

Principal Investigators

  • Yong Song, Ph.D · Nanjing PLA General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-07
Primary Completion
2017-04-10
Completion
2018-04-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01933347 on ClinicalTrials.gov